Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

  • Revenue in USD (TTM)862.69m
  • Net income in USD-1.17bn
  • Incorporated2010
  • Employees5.40k
  • Location
    Beigene LtdC/O Mourant Governance Services (Cayman)94 Solaris Avenue, Camana BayBEIJING 102206ChinaCHN
  • Phone+1 3 459494123
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cardinal Health Inc156.57bn1.15bn16.19bn48.00k14.269.078.150.10343.913.91533.006.153.6811.0317.653,261,875.002.71-0.14696.59-0.34164.404.950.737-0.04080.6331--0.7896--5.088.32-371.17--4.567.03
EXACT Sciences Corporation1.49bn-848.53m16.49bn4.80k--5.43--11.06-5.54-5.549.8717.710.35384.608.20310,706.50-20.13-16.06-22.28-17.6476.2474.55-56.90-43.593.66-1.800.3617--70.19106.79-910.24--84.98--
Catalent Inc3.76bn496.80m17.29bn13.90k34.294.6522.184.602.962.9622.4623.940.47425.734.30270,316.507.033.108.073.5333.2031.5314.825.881.955.670.44180.0022.8911.0725.91-3.9927.00--
Incyte Corporation2.70bn478.48m18.12bn1.77k37.926.6434.116.702.172.1712.2812.410.84287.287.221,524,486.0014.920.421118.100.502295.8795.9517.700.55393.90--0.01250.0023.5328.75-166.17--48.44--
Novocure Ltd527.23m11.73m18.60bn1.02k1,715.4449.86870.6435.270.10480.10484.903.610.67164.306.69515,379.301.49-14.201.71-16.7379.4472.622.22-21.468.942.690.6006--40.7271.74218.11--7.82--
Viatris Inc13.76bn-1.73bn19.00bn45.00k--0.887216.171.38-1.50-1.5017.7717.720.30872.314.35305,713.30-3.880.5608-4.680.670836.2140.67-12.561.710.73932.510.53250.003.874.85-4,087.50---4.81--
Gartner Inc4.18bn355.75m19.20bn15.60k56.1621.7833.314.593.973.9746.6310.240.6092--3.54268,240.405.182.728.474.7668.0263.328.504.17--6.110.68840.00-3.4413.6414.348.7212.71--
Horizon Therapeutics PLC2.19bn280.04m19.46bn1.64k75.085.0434.468.901.151.159.9917.160.35973.505.041,567,689.004.611.345.191.6075.5167.8112.814.262.068.030.40080.0069.2623.79-31.9858.0488.40--
AmerisourceBergen Corp.196.28bn-3.75bn24.67bn22.00k------0.1257-18.43-18.43953.13-1.374.4115.8612.728,921,921.00-8.410.1172-31.670.48112.832.81-1.910.02550.682316.441.02655.335.746.91-516.53--9.817.43
Seagen Inc2.27bn660.65m26.27bn2.09k40.197.6736.3711.563.603.6012.5818.890.75332.188.111,086,523.0021.90-0.423124.52-0.48988.8990.3929.07-0.71687.59--0.00--137.3245.22486.81--43.82--
Beigene Ltd (ADR)862.69m-1.17bn29.46bn5.40k--7.19--34.15-13.68-13.649.7643.470.17451.7511.53162,771.10-23.72-42.83-28.23-51.2589.66---135.96-297.994.56-136.820.13---27.87103.66-58.17--111.90--
McKesson Corporation238.23bn-4.54bn31.37bn59.00k------0.1317-28.57-28.581,478.99-0.13293.7712.5712.184,037,763.00-6.870.5468-23.811.615.105.35-1.820.1520.592615.200.8317182.633.114.53-600.88---1.099.80
Data as of May 12 2021. Currency figures normalised to Beigene Ltd's reporting currency: US Dollar USD

Institutional shareholders

45.94%Per cent of shares held by top holders
HolderShares% Held
Baker Bros. Advisors LPas of 04 Jan 202111.67m12.73%
Hillhouse Capital Advisors Ltd.as of 31 Dec 20205.47m5.97%
Capital Research & Management Co. (International Investors)as of 31 Dec 20205.37m5.85%
Fidelity Management & Research Co. LLCas of 31 Dec 20204.69m5.11%
Baillie Gifford & Co.as of 31 Mar 20214.43m4.83%
PRIMECAP Management Co.as of 31 Dec 20203.37m3.67%
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Dec 20202.65m2.89%
BlackRock Fund Advisorsas of 31 Dec 20201.93m2.10%
Wellington Management Co. LLPas of 31 Dec 20201.44m1.57%
Tavistock Life Sciences Co. (Investment Management)as of 31 Dec 20201.11m1.22%
More ▼
Data from 31 Dec 2020 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.